Yayıncı "American Society of Hematology" Bildiri Koleksiyonu için listeleme
Toplam kayıt 12, listelenen: 1-12
-
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
(American Society of Hematology, 2023)Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ... -
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
(American Society of Hematology, 2022)Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ... -
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
(American Society of Hematology, 2022)Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ... -
Different response patterns to inactivated, subunit or live attenuated vaccines in children after treatment for malignancies and bone marrow transplantation
(American Society of Hematology, 2015)... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
(American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ... -
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ... -
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
(American Society of Hematology, 2021)... -
Is the end close for the graft-versus-host disease that is a big problem following allogeneic hematopoetic stem cell transplantation?
(American Society of Hematology, 2018)… -
Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study
(American Society of Hematology, 2022)Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients ... -
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ... -
Prospective real-world outcomes of acute myeloid leukemia
(American Society of Hematology, 2023)Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ... -
Retrospective analysis of Turkish AML registry database, on behalf of AML working group of Turkish society of hematology
(American Society of Hematology, 2022)Abstract Introduction: To investigate the demographics and treatment details of the acute myeloid leukemia (AML) patients who were diagnosed and followed up in Turkey. Methods: Patients who were recorded on the database ...